111 -11 (49) 2022 — Sanoeva M.J. — MANIFESTATION OF COGNITIVE DYSFUNCTION IN MULTIPLE SCLEROSIS WITH COVID-19 (SARS-COV-2)

MANIFESTATION OF COGNITIVE DYSFUNCTION IN MULTIPLE SCLEROSIS WITH COVID-19 (SARS-COV-2)

Sanoeva M.J. Bukhara State Medical Institute, Uzbekistan

Resume

The COVID-19 pandemic worldwide, first identified at the end of 2019 in the People’s Republic of China (PRC), in the city of Wuhan (Hubei), affects not only the brain and spinal cord, but also other organs and systems, in connection with which an in-depth study and development of new diagnostic tools are still ongoing, treatment and prevention of its complications. The aim of the study was to study cognitive functions in patients with multiple sclerosis in COVID-19 (infected with SARS-CoV-2). 42 patients with multiple sclerosis were studied – 24 (57.1%) suffered COVID-19 of varying severity (group 1, comparative), and 18 (42.9%) remained intact (group 2, main). All patients underwent a PCR analysis confirming infection with SARS-CoV-2, a study of C-reactive protein, the number of leukocytes, D-demir, urea and creatinine in venous blood. Cognitive impairment developed not only in patients with multiple sclerosis infected with coronavirus infection, but also in similar patients without COVID-19. More extensive neuropsychological testing and analysis of the relationship of inflammatory markers (ESR, blood leukocytes, CRP) and MSCT were performed. The analyses were compared retrospectively and prospectively, 10-12 days after infection, at the stage of recovery. The presence of coronavirus pathology in patients with multiple sclerosis led to an aggravation of the clinical picture of the disease, mutually burdening each other, with a significant impact on the quality of life, the development of disability, through motor, somatosensory, visual, cognitive and neuropsychic disorders.

Key words: manifestation of cognitive dysfunctions, patients with multiple sclerosis, COVID-19, SARS-COV-2 virus.

First page

647

Last page

654

For citation: Sanoeva M.J. – MANIFESTATION OF COGNITIVE DYSFUNCTION IN MULTIPLE SCLEROSIS WITH COVID-19 (SARS-COV-2) //New Day in Medicine 11(49)2022 647-654 https://clck.ru/32vgdA

LIST OF REFERENCES:

  1. Бойко А.Н., Сиверцева С.А., Спирин Н.Н. Поражение нервной системы при инфекции COVID-19 с акцентом на ведение пациентов с рассеянным склерозом // Неврология, нейропсихиатрия, психосоматика. 2020;12(Прил. 1):44-7. doi: 10.14412/2074- 2711-2020-1S-44-47.
  2. Гусев Е.И., Мартынов М.Ю., Бойко А.Н. и др. Новая коронавирусная инфекция (COVID-19) и поражение нервной системы: механизмы неврологических расстройств, клинические проявления, организация неврологической помощи //Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(6):7-16 doi: 10.17116/jnevro20201200617.
  3. Саноева М.Ж., Гиязова М.М. Некоторые патогенетические аспекты и особенности поражения структур полости рта при коронавирусной инфекции (Обзор) //Журнал неврологии и нейрохирургических исследований. 2021; -№4 – С 48-52. doi: http//dx.doi.org. /10.5281/zenodo.5807834.
  4. Barts MS. SARS-CoV2 vaccine advice for people with Multiple Sclerosis. https://multiple-sclerosisresearch.org/2021/01/bartsms-covid-19-vaccineadvice-update.
  5. Bar-Or A., Calkwood J.C., Chognot C. et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology. 2020;95(14): e1999-e2008. doi: 10.1212/WNL.0000000000010380.
  6. Bar-Or A., Freedman M.S., Kremenchutzky M., et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. //Neurology. 2013 Aug 6;81(6):552-8. doi: 10.1212/WNL.0b013e31829e6fbf.
  7. Ciotti J., Valtcheva M., Cross A. Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord. 2020 Oct; 45:102439. doi: 10.1016/j.msard.2020.102439. Epub 2020 Aug 1
  8. Farez M., Correale J., Armstrong M.J. et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. //Neurology. 2019 Sep 24;93(13):584-94. doi: 10.1212/WNL.0000000000008157.
  9. Giovannoni G., Hawkes Ch., Lechner-Scott J. et al. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord. 2020 Apr; 39:102073. doi: 10.1016/j.msard.2020.102073.
  10. Giyazova M. M. Modern Treatment of Diseases of the Oral Mucosa and Periodontal Under the Influence of Covid 19 //International Journal on Integrated Education. -2021; -Vol. 4, Issue 10. – P. 96-98.
  11. Giyazova M. M. Structure Of Treatment of Diseases of The Oral Mucosa and Periodontal Under the Influence of Covid 19 //Eurasian Scientific Herald. -2021; -Vol.3; – P. 37-40.
  12. Kappos L., Mehling M., Arroyo R. et al. Randomized trial of vaccination in fingolimod treated patients with multiple sclerosis. Neurology. 2015 Mar 3;84(9):872-9. doi: 10.1212/WNL.0000000000001302. Epub 2015 Jan 30.
  13. Kaufman M., Pardo G., Rossman H. et al. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. //J Neurol Sci. 2014 Jun 15;341(1-2):22- 7. doi: 10.1016/j.jns.2014.03.035. Epub 2014 Mar 26.
  14. Lebrun C., Vukusic S. Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society. Mult Scler Relat Disord. 2019 Jun; 31:173-88. doi: 10.1016/j.msard.2019.04.004.
  15. Louapre C., Collongues N., Stankoff B. et al. Clinical Characteristics and Outcomes in Patients with Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol. 2020 Sep 1;77(9):1079-88. doi: 10.1001/jamaneurol.2020.2581.
  16. Mares J., Hartung H.P. Multiple sclerosis and COVID-19. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Sep;164(3):217-25. doi: 10.5507/bp.2020.033.
  17. McCarthy C.L., Tuohy O., Compston D.A.S. et al. Immune competence after alemtuzumab treatment of multiple sclerosis. //Neurology. 2013 Sep 3;81(10):872-6. doi: 10.1212/WNL.0b013e3182a35215. Epub 2013 Aug 7.
  18. MS International Federation. Global COVID-19 advice for people with MS.: https://www.msif.org/news/2020/02/10/thecoronavirus-and-ms-what-you-need-to-know.
  19. MS Society Medical Advisers consensus statement on MS treatment.: https://www.mssociety.org.uk/whatwe-do/news/ms-society-medical-advisersrelease-consensus-statement-covid-19-vaccines.
  20. National MS Society. COVID-19 vaccine guidance for people living with MS.:https://www.nationalmssociety.org/coronaviruscovid-19-information/multiple-sclerosis-andcoronavirus/covid-19-vaccine-guidance#section-1.

file

download